Objective To observe the clinical efficacy and safety of Shengmai capsules in the treatment of chronic congestive heart failure.Methods Eighty-four patients with chronic congestive heart failure were randomly divided into control group and treatment group with 42 cases per group.Control group was given placebo 0.3 mg each time,tid,orally.Treatment group was given Shengmai capsule 0.3 mg each time,tid,orally.Two groups were treated for 2 weeks.The clinical efficacy,heart rate,left ventricular ejection fraction (LVEF),maximal velocity of bicuspid blood flow in the early (E),E/ maximal velocity of bicuspid blood flow in the advanced (E/A),pulmonary artery pressure (PAS),heart function echocardiographic multi-parameter scores (HF-EMPS) and adverse drug reactions were compared between two groups.Results After treatment,the total effective rates of treatment and control groups were 90.47％ (38 cases/42 cases) and 73.81％ (31 cases/42 cases) with significant difference (P ＜ 0.05).After treatment,the main indexes in treatment and control groups were compared:heart rate were (66.54 ±7.02) and (72.12 ± 8.14) beat · min-1,LVEF were (46.03 ±5.56)％ and (41.26 ±5.12)％,E were(92.48 ±14.32)and(75.41 ± 13.62)cm · s-1,E/A were 1.65±0.34 and 1.35 ± 0.31,PAS were (24.85 ± 4.21) and (30.12 ± 4.22) mmHg,HF-EMPS were (7.03 ±1.12) and (7.68 ± 1.32)points with significant difference (all P ＜ 0.05).There were no adverse drug reactions occurred during the treatment in two groups.Conelusion Shengmai capsules have a definitive clinical efficacy and safety in the treatment of chronic congestive heart failure.

Objective To investigate the long-term effects of non-surgical treatment on clinical and hematologic states of patients with generalized aggressive periodontitis (GAgP).Methods Patients with GAgP(n =25) and healthy controls (n =28) were recruited.The clinical parameters,including probing depth(PD),bleeding index(BI),attachment loss(AL) were examined and recorded.Blood cell variables,including white blood cells (WBC),leukocyte,neutrophil,and lymphocyte counts,as well as serum triglycerides,fasting glucose and protein parameters,including total protein,albumin,globulin,and albumin/globulin ratio(A/G),were analyzed.Twenty-five GAgP patients received non-surgical treatment and the clinical and blood parameters 3 to 7 years after treatment were re-evaluated.Clinical and hematological parameters of the two groups were compared.Comparisons of clinical and hematologic parameters pre-and post-treatment in GAgP group were performed through one-way ANOVA and paired-t test.Results Elevated white blood cells,neutrophil numbers and serum total protein,globulin levels were observed in patients with GAgP compared to controls [(6.3 ± 2.0) × 109cell/L vs.(5.4 ± 1.0) ×109cell/L,(4.1 ±1.8) × 109 cell/L vs.(3.0 ±0.9) × 109 cell/L,(78.2 ±4.4) g/L vs.(75.6 ±4.6) g/L and (29.3 ±3.8) g/L vs.(26.5 ±3.9) g/L respectively,P ＜0.05].A/G ratio was lower in the GAgP group than in the control group (1.7 ±0.2 vs.1.9 ±0.3,P ＜0.01).Three to seven years after periodontal treatment,the reduction of PD and BI was observed in GAgP group (P ＜ 0.05).There were significant decreases of WBC count,neutrophil count,serum total protein and globulin level,and significant increases of albumin level and A/G at 3 to 7 years after treatment (P ＜ 0.05).Conclusions Non-surgical treatment may have long-term beneficial effect on the periodontal clinical status and hematologic parameters of generalized aggressive periodontitis.

Objective To investigate the effect of hyperbaric oxygen preconditioning on the expression of lung aquaporin-1 in the rat models of high altitude pulmonary edema. Methods Thirty-eight Wistar rats were randomly divided into 3 groups: the control group (the C group ),the HBO group and the high-altitude pulmonary edema group (the HAPE group). Western blot and real-time PCR were applied to determine the expression of AQP-1 in the lung of animals in each group. The wet-to-dry weight ratio ( W/D weight ratio) and morphology of the lung were also examined. Results Experiments showed that the W/D weight ratio of the HAPE group was obviously higher than that of the C group,lung injury scores of the HBO group were much lower than those of the HAPE group,AQP-1 and AQP-1 mRNA for the HAPE group decreased markedly at the protein and gene level than those of the C group,and that AQP-1 and AQP-1 mRNA for the HBO group were significantly higher than those of the HAPE group. Conclusions Decreased expression of AQP-1 might be involved in the mechanism of HAPE incidence. HBO preconditioning could positively regulate the expression of AQP-1 and at the same time prevent and alleviate effects of HAPE. Our study might be the first one introducing HBO preconditioning in the prevention of HAPE,and the first investigation on the expression of AQP-1 in a rat model of HAPE.

Objective To investigate the effect of hyperbaric oxygen preconditioning on the expression of lung aquaporin-1 in the rat models of high altitude pulmonary edema. Methods Thirty-eight Wistar rats were randomly divided into 3 groups: the control group (the C group ),the HBO group and the high-altitude pulmonary edema group (the HAPE group). Western blot and real-time PCR were applied to determine the expression of AQP-1 in the lung of animals in each group. The wet-to-dry weight ratio ( W/D weight ratio) and morphology of the lung were also examined. Results Experiments showed that the W/D weight ratio of the HAPE group was obviously higher than that of the C group,lung injury scores of the HBO group were much lower than those of the HAPE group,AQP-1 and AQP-1 mRNA for the HAPE group decreased markedly at the protein and gene level than those of the C group,and that AQP-1 and AQP-1 mRNA for the HBO group were significantly higher than those of the HAPE group. Conclusions Decreased expression of AQP-1 might be involved in the mechanism of HAPE incidence. HBO preconditioning could positively regulate the expression of AQP-1 and at the same time prevent and alleviate effects of HAPE. Our study might be the first one introducing HBO preconditioning in the prevention of HAPE,and the first investigation on the expression of AQP-1 in a rat model of HAPE.

Objective To evaluate the safety and efficiency of the dobutamine stress echocardiography in patients with hypertrophic cardiomyopathy and estimate the difference between provokable obstruction and resting obstruction in these patients.nethods Echocardiogarphy was performed in 22 patients with HCM(LVOTPG<50 mm Hg at rest, 1 mm Hg=0.133 kPa)at rest and at the end point of dobutamine stress.Dobutamine was administered via an infusion pump, starting at a dose of 5 μg·min-1·kg-1 and increasing every 5 minutes by 5μg·min-1·kg-1 till the maximum dose of 20μg·min-1·kg-1.Fifty-seven patients with HCM(LVOTPG>50 mm Hg at rest)were also studied at rest.Results In these 22 patients, the mean maximum velocity of LVOT was 5.39±1.60 m/s, the mean maximum LVOTPG was 125.7±62.4 mm Hg at the end point of dobutamine stress and the mean dose of dobutamine Was 13.90 ±6.85 μg·min-1·kg-1.Sixteen patients evidenced positive stress results at the end point of dobutamine stress.The main difference between the provokable obstruction and resting obstruction was that in provokable obstruction patients, the SAM positive patients were fewer and the proportion of Maron Ⅱ patients was higher(50%).Conclusions Dobutamine stress echocardiography Was a safe and sensitive way for detecting patients with hypertrophic cardiomyopathy.Provokable obstruction patients had fewer SAM and higher proportion of Maron Ⅱ.